These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 32395382)

  • 21. A microRNA signature associated with pathological complete response to novel neoadjuvant therapy regimen in triple-negative breast cancer.
    García-Vazquez R; Ruiz-García E; Meneses García A; Astudillo-de la Vega H; Lara-Medina F; Alvarado-Miranda A; Maldonado-Martínez H; González-Barrios JA; Campos-Parra AD; Rodríguez Cuevas S; Marchat LA; López-Camarillo C
    Tumour Biol; 2017 Jun; 39(6):1010428317702899. PubMed ID: 28621239
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Factors affecting pathological complete response after neoadjuvant chemotherapy in breast cancer: a single-center experience.
    Mermut O; Inanc B; Gursu RU; Arslan E; Trabulus DC; Havare SB; Ulusan MB
    Rev Assoc Med Bras (1992); 2021 Jun; 67(6):845-850. PubMed ID: 34709328
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Magnetic resonance imaging tumor regression shrinkage patterns after neoadjuvant chemotherapy in patients with locally advanced breast cancer: Correlation with tumor biological subtypes and pathological response after therapy.
    Ballesio L; Gigli S; Di Pastena F; Giraldi G; Manganaro L; Anastasi E; Catalano C
    Tumour Biol; 2017 Mar; 39(3):1010428317694540. PubMed ID: 28347225
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection.
    Lehmann BD; Jovanović B; Chen X; Estrada MV; Johnson KN; Shyr Y; Moses HL; Sanders ME; Pietenpol JA
    PLoS One; 2016; 11(6):e0157368. PubMed ID: 27310713
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Magnetic resonance imaging in breast cancer treated with neoadjuvant chemotherapy: radiologic-pathologic correlation of the response and disease-free survival depending on molecular subtype.
    Cruz Ciria S; Jiménez Aragón F; García Mur C; Esteban Cuesta H; Gros Bañeres B
    Radiologia; 2014; 56(6):524-32. PubMed ID: 23294850
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Erratum: High-background parenchymal enhancement in the contralateral breast is an imaging biomarker for favorable prognosis in patients with triple-negative breast cancer treated with chemotherapy.
    Xu C; Yu J; Wu F; Li X; Hu D; Chen G; Wu G
    Am J Transl Res; 2023; 15(7):4970. PubMed ID: 37560220
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Magnetic resonance examination to predict pathological complete response following neoadjuvant chemotherapy: when is it appropriate for HER2-positive and triple-negative breast cancers?
    Okamoto S; Yamada T; Kanemaki Y; Kojima Y; Tsugawa K; Nakajima Y
    Breast Cancer; 2016 Sep; 23(5):789-96. PubMed ID: 26437647
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Response and survival of breast cancer intrinsic subtypes following multi-agent neoadjuvant chemotherapy.
    Prat A; Fan C; Fernández A; Hoadley KA; Martinello R; Vidal M; Viladot M; Pineda E; Arance A; Muñoz M; Paré L; Cheang MC; Adamo B; Perou CM
    BMC Med; 2015 Dec; 13():303. PubMed ID: 26684470
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Assessment of Residual Disease With Molecular Breast Imaging in Patients Undergoing Neoadjuvant Therapy: Association With Molecular Subtypes.
    Menes TS; Golan O; Vainer G; Lerman H; Schneebaum S; Klausner J; Even-Sapir E
    Clin Breast Cancer; 2016 Oct; 16(5):389-395. PubMed ID: 27282845
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Local-regional control according to surrogate markers of breast cancer subtypes and response to neoadjuvant chemotherapy in breast cancer patients undergoing breast conserving therapy.
    Caudle AS; Yu TK; Tucker SL; Bedrosian I; Litton JK; Gonzalez-Angulo AM; Hoffman K; Meric-Bernstam F; Hunt KK; Buchholz TA; Mittendorf EA
    Breast Cancer Res; 2012 May; 14(3):R83. PubMed ID: 22621334
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Impact of pathological complete response to neoadjuvant chemotherapy in invasive breast cancer according to molecular subtype].
    Cirier J; Body G; Jourdan ML; Bedouet L; Fleurier C; Pilloy J; Arbion F; Ouldamer L
    Gynecol Obstet Fertil Senol; 2017 Oct; 45(10):535-544. PubMed ID: 28939364
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The accuracy of
    Tian F; Shen G; Deng Y; Diao W; Jia Z
    Eur Radiol; 2017 Nov; 27(11):4786-4796. PubMed ID: 28477166
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Association between efficacy and molecular subtypes in breast cancer patients receiving neoadjuvant chemotherapy].
    Niu HF; Wei LJ; Lian Z; Zhao J; Li LJ; Wu ZZ; Liu JT
    Zhonghua Zhong Liu Za Zhi; 2016 Mar; 38(3):190-6. PubMed ID: 26988824
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Correlating transcriptional networks with pathological complete response following neoadjuvant chemotherapy for breast cancer.
    Liu R; Lv QL; Yu J; Hu L; Zhang LH; Cheng Y; Zhou HH
    Breast Cancer Res Treat; 2015 Jun; 151(3):607-18. PubMed ID: 25981901
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Androgen Receptor Expression in an Indian Breast Cancer Cohort with Relation to Molecular Subtypes and Response to Neoadjuvant Chemotherapy - a Prospective Clinical Study.
    Anand A; Singh KR; Kumar S; Husain N; Kushwaha JK; Sonkar AA
    Breast Care (Basel); 2017 Jul; 12(3):160-164. PubMed ID: 28785183
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Discrepancies Between Pathological Tumor Responses and Estimations of Complete Response by Magnetic Resonance Imaging After Neoadjuvant Chemotherapy Differ by Breast Cancer Subtype.
    Namura M; Tsunoda H; Yagata H; Hayashi N; Yoshida A; Morishita E; Takei J; Suzuki K; Yamauchi H
    Clin Breast Cancer; 2018 Apr; 18(2):128-134. PubMed ID: 28843513
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Corrigendum: PAM50 Subtypes in Baseline and Residual Tumors Following Neoadjuvant Trastuzumab-Based Chemotherapy in HER2-Positive Breast Cancer: A Consecutive-Series From a Single Institution.
    Pernas S; Petit A; Climent F; Paré L; Perez-Martin J; Ventura L; Bergamino M; Galván P; Falo C; Morilla I; Fernandez-Ortega A; Stradella A; Rey M; Garcia-Tejedor A; Gil-Gil M; Prat A
    Front Oncol; 2019; 9():967. PubMed ID: 31598491
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prediction of pathological complete response of breast cancer patients undergoing neoadjuvant chemotherapy: usefulness of breast MRI computer-aided detection.
    Kim H; Kim HH; Park JS; Shin HJ; Cha JH; Chae EY; Choi WJ
    Br J Radiol; 2014 Nov; 87(1043):20140142. PubMed ID: 25162970
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Neoadjuvant Chemotherapy for Breast Cancer: Moving Beyond Pathological Complete Response in the Molecular Age.
    Provenzano E
    Acta Med Acad; 2021 Apr; 50(1):88-109. PubMed ID: 34075766
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Combinational Treatment of Doxorubicin With Neoadjuvant Docetaxel for Different Subtypes of Patients With Breast Cancer.
    Wang LC; Wang LS; Li AX; Shi ZZ; Li YQ; Huang W; Chen SM; Han F; Zhu DQ
    Technol Cancer Res Treat; 2020; 19():1533033820928435. PubMed ID: 32508292
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.